BioCryst Pharmaceuticals, Inc. (BMV:BCRX)
Mexico
· Delayed Price · Currency is MXN 138.00
0.00 (0.00%)
At close: Apr 29, 2025
BioCryst Pharmaceuticals Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Net Income | -88.88 | -226.54 | -247.12 | -184.06 | -182.81 | Upgrade
|
| Depreciation & Amortization | 3.01 | 2.87 | 2.25 | 0.89 | 0.75 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 1.55 | - | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | -11.47 | -10.26 | -1.78 | -0 | 0.12 | Upgrade
|
| Stock-Based Compensation | 65.41 | 55.62 | 44.7 | 34.64 | 14.79 | Upgrade
|
| Other Operating Activities | 67.19 | 114.03 | 99.03 | -1.75 | 5.17 | Upgrade
|
| Change in Accounts Receivable | -22.7 | -6.1 | -21.47 | -20.82 | 13.9 | Upgrade
|
| Change in Inventory | -4.16 | -1.45 | -12.42 | -8.77 | -7.04 | Upgrade
|
| Change in Accounts Payable | -62.38 | -16.81 | -22.36 | 39.41 | 17.36 | Upgrade
|
| Change in Unearned Revenue | - | -1.23 | -0.11 | 1.28 | -1.97 | Upgrade
|
| Change in Other Net Operating Assets | 1.96 | -6.82 | -2.58 | -2.99 | 4.63 | Upgrade
|
| Operating Cash Flow | -52.02 | -95.14 | -161.85 | -142.16 | -135.11 | Upgrade
|
| Capital Expenditures | -1.12 | -2.17 | -1.35 | -2.39 | -0.51 | Upgrade
|
| Investment in Securities | 53.72 | -129.33 | -126.89 | 18.19 | -6.34 | Upgrade
|
| Investing Cash Flow | 52.59 | -131.5 | -128.24 | 15.8 | -6.86 | Upgrade
|
| Long-Term Debt Issued | - | 300 | 73.07 | 293.87 | 242.47 | Upgrade
|
| Long-Term Debt Repaid | -1.7 | -241.62 | - | - | -52.42 | Upgrade
|
| Net Debt Issued (Repaid) | -1.7 | 58.38 | 73.07 | 293.87 | 190.05 | Upgrade
|
| Issuance of Common Stock | 3.48 | 8.68 | 14.96 | 65.79 | 95.73 | Upgrade
|
| Other Financing Activities | -7.54 | -34.58 | - | - | 14.82 | Upgrade
|
| Financing Cash Flow | -5.76 | 32.49 | 88.03 | 359.67 | 300.59 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.94 | 0.36 | 0.57 | 0.07 | - | Upgrade
|
| Net Cash Flow | -6.12 | -193.79 | -201.5 | 233.39 | 158.63 | Upgrade
|
| Free Cash Flow | -53.14 | -97.31 | -163.2 | -144.54 | -135.62 | Upgrade
|
| Free Cash Flow Margin | -11.79% | -29.36% | -60.26% | -91.97% | -761.41% | Upgrade
|
| Free Cash Flow Per Share | -0.26 | -0.51 | -0.88 | -0.81 | -0.81 | Upgrade
|
| Cash Interest Paid | 30.38 | 22.14 | - | 0.9 | - | Upgrade
|
| Cash Income Tax Paid | 1.6 | 1.43 | 3.54 | 0.12 | - | Upgrade
|
| Levered Free Cash Flow | 11.95 | -67.23 | -141.51 | -122.67 | -73.33 | Upgrade
|
| Unlevered Free Cash Flow | 73.52 | 0.42 | -79.58 | -85.61 | -64.27 | Upgrade
|
| Change in Net Working Capital | -7.02 | -5.84 | 32.41 | 7.68 | -26.78 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.